Assembly Biosciences Posts Q1 Net Loss of $9.1M, $226.6M Cash; Advances Clinical Candidates
ASMB•Assembly Biosciences reported Q1 2026 net loss of $9.1 million with cash on hand of $226.6 million, extending runway into 2028. The company completed Phase 1b trials of herpes candidates ABI-5366 and ABI-1179 and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, targeting Phase 2 in Q4 2026.
1. Q1 Financial Results
Assembly Biosciences posted a net loss of $9.1 million for the first quarter of 2026, driven primarily by research and development and administrative expenses.
2. Cash Position and Runway
As of March 31, the company held $226.6 million in cash, cash equivalents and marketable securities, a balance management expects will fund operations into 2028.
3. Clinical Development Updates
The firm completed Phase 1b studies for its herpes pipeline candidates ABI-5366 and ABI-1179 (licensed to a partner) and concluded chronic toxicology tests for its hepatitis delta virus candidate ABI-6250, with Phase 2 initiation slated for Q4 2026.
